An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

An Open Label, Double-blind Discontinuation Study of Quetiapine (Extended Release) XR in Social Anxiety Disorder

Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2) continuation effects of quetiapine XR in preventing SAD relapse.

Inclusion Criteria:

• Adults 18-65 years of age
• A primary diagnosis of SAD,using Diagnostic Standard Manual IV(DSM-IV) criteria
• Minimum CGI severity score of 4 and minimum Brief Social Phobia Scale (BSPS) score of 20 at baseline
• Written informed consent
• A negative serum pregnancy test for women of childbearing potential.

Exclusion Criteria:

• Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition
• Any current primary anxiety disorder other than SAD or current primary depression
• History of substance abuse or dependence within the last 6 months
• Suicide risk or serious suicide attempt within the last year
• Clinically significant medical condition or laboratory abnormality
• Women of childbearing potential who are unwilling to practice an acceptable method of contraception
• Subjects needing concurrent use of psychotropic medications
• History of hypersensitivity to quetiapine
• History of cataracts.